Kornimate/medical-research-clean huggingface dataset:
neoadjuvant therapy of darolutamide plus adt for high risk prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to determine if treatment with darolutamide plus androgen deprivation therapy (adt) before radical prostatectomy (rp) with pelvic lymph node dissection (plnd) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pcr) rate and pathological tumor volume with minimal residual disease (mrd)) as compared to adt.


Eligibility criteria:
inclusion criteria: * patients must be ≥ 18 and ≤75 years of age. * all patients must have a histologically or cytologically diagnosis of prostate cancer and must be eligible for radical prostatectomy. * eastern cooperative oncology group (ecog) performance status score ≤1. * all patients must complete mpmri or 68ga-psma pet / ct before and after neoadjuvant treatment. * all patients must undergo thorough tumor staging and meet one of the following criteria: 1. multi-parameter mri or psma pet / ct shows clinical staging of primary tumor ≥ ct2c or cn+or locally advanced, 2. gleason score of primary tumor ≥ 8, 3. prostate specific antigen (psa) ≥20 ng/ml. * patients must have adequate organ function as defined by the following criteria(within 28 days prior to registration): white blood cell (wbc) ≥ 4.0 × 109 / l platelets≥ 100 × 109 / l hemoglobin ≥ 9 g / dl international normalized ratio (inr) \< 1.5. total bilirubin (tbil)≤1.5 x upper limit of normal (uln) sgot (ast) and sgpt (alt) ≤ 2.5 x uln serum creatinine ≤2×uln * patients must participate voluntarily and sign an informed consent form (icf), indicating that they understand the purpose and required procedures of the study, and are willing to participate in. patients must be willing to obey the prohibitions and restrictions specified in the research protocol. exclusion criteria: * clinical or radiological evidence of regional or extra-regional lymph node metastases or bone metastases or visceral metastases. * prior androgen deprivation therapy (medical or surgical) or focal treatment of prostate cancer or prostate cancer radiotherapy or prostate cancer chemotherapy. * severe or uncontrolled concurrent infections. * new york heart association class iii or iv congestive heart failure at the time of screening. * uncontrolled severe hypertension, persistent uncontrolled diabetes, oxygen-dependent lung disease, chronic liver disease, or hiv infection. * patients with mental illness, mental disability or inability to give informed consent are not eligible. * patients have had other malignancies other than prostate cancer in the past 5 years, but cured basal cell or squamous cell skin cancers can be enrolled.
ca 125 and vas pain score changes to diagnose endometriosis

Conditions: Pelvic Pain; Endometriosis

Summary: to assess the diagnostic accuracy for the noninvasive detection of pelvic endometriosis of the combination of two simple parameters: modifications of serum ca 125 and vas pain score following one dose of gnrh-analog (gnrh-a).

between january 2010 and january 2014, women scheduled for a diagnostic laparoscopy for cpp at our department will be enrolled in the current prospective observational study. for these patients, laparoscopy represents the last diagnostic step after medical history negative for gastrointestinal, urological, musculoskeletal and psychoneurological disorders related to pelvic pain, physical examination, ultrasonographic assessment and laboratory testing. from all patients, at enrollment, blood samples for serum ca125 determination will be taken during the early follicular phase (2nd-3rd day of the menstrual cycle) and vas score for menstrual pain will be assessed. electrochemiluminescence immunoassay (immunoassay elecsys systems, roche diagnostics, italy) for serum ca125 assay will be used (kit coefficient of variation between-run 0.0% and within-run 2.0%). during the time passed on surgery waiting list, patients will received leuprolide acetate depot (lad) at a dose of 3.75 mg im at the 21st day of the menstrual cycle. one month later lad administration, serum ca125 levels and vas score will be assessed again, and then the surgical procedure will be performed in all these patients. after laparoscopy and definitive histological examination, the population initially enrolled will be sub-grouped according to endometriosis diagnosis in two groups, i.e. group 1 (subjects with endometriosis) and group 2 (subjects without endometriosis).

Eligibility criteria:
inclusion criteria: * chronic pelvic pain exclusion criteria: * age less than 18 and greater than 38 * oligo-amenorrhea * use of hormone medications (including oral contraceptives pill, progestogens, and so on) * conditions affecting serum ca125 levels (such as, pregnancy, ovarian endometrioma seen at ultrasonography, pelvic inflammatory diseases, neoplasm, tuberculosis, hepatitis, peritonitis, recent abdominal surgery and pelvic organic disease)

Keywords: gnrh-a endometriosis chronic pelvic pain vas score diagnostic accuracy
ibd and women's health wellness program

Conditions: Inflammatory Bowel Diseases; Ulcerative Colitis; Crohn Disease

Summary: researchers want to understand if a combination of usual medical care along with a wellness program designed for women with inflammatory bowel disease diagnosis will have an effect on quality of life, stress, and disease activity.

it will take a year to complete the study and involves subjects participating in a wellness program, wellness coaching and completion of surveys. subjects will be requested to complete wellness classes along with one wellness coaching session within the first two months of study participation, and continue their year long participation of wellness coaching sessions and surveys.

Eligibility criteria:
inclusion criteria: * female patient with a diagnosis of ulcerative colitis or crohn's disease seen in the inflammatory bowel disease clinic in the division of gastroenterology and hepatology at mayo clinic in rochester. * who are between 18-64 years of age. * ability to provide informed consent. * ability to complete all aspects of this trial. exclusion criteria: * female patients with a diagnosis of ulcerative colitis or crohn's disease with medical co-morbidity or factor judged by the investigator to preclude participation in the study or which might hinder adherence. * participation in another organized wellness program.
laparoscopic partial nephrectomy for ct1 tumors

Conditions: Renal Cancer; Renal Neoplasm; Renal Cell Carcinoma; Surgery; Surgery--Complications; Renal Functional Abnormality; Oncology; Oncology Problem; Kidney Ischemia; Kidney Injury; Urologic Neoplasms; Urologic Cancer; Kidney Neoplasms

Summary: the aim of the study is to evaluate trifecta and pentafecta outcomes for laparoscopic partial nephrectomy (lnp) in patients with clinical t1n0m0 renal tumor.

from november 2009 to august 2018 a total of 292 patients who underwent lpn by global ischemia were included in the study. the patients were allocated into two groups according to the tumor size; t1a (≤ 40 mm, n=215), t1b (41-70 mm, n=77). demographics features, clinical tumor characteristics, intraoperative and postoperative outcomes were analyzed. a negative surgical margin, warm ischemia time (wit) \ 90% preservation of estimated glomerular filtration rate (egfr) and no stage upgrade of chronic kidney disease 12 months after lpn. univariable and multivariable analysis were used to identify factors predicting trifecta and pentafecta achievement.

Eligibility criteria:
inclusion criteria: * functioning contraleteral kidney * patients with complete data * patients with single renal tumor on the effected side * patients who approved the written consent form exclusion criteria: * the patients with bilateral renal tumors (n=8, 16 lpns) * solitary kidney (n=8) * horseshoe kidney (n=4) * pelvic ectopic kidney (n=2) * graft kidney (n=2) * those with multiple renal tumors in a single kidney (n=3) or with \> 7 cm renal tumor (n=6) * patients who were operated on for colon cancer (n=4), prostate cancer (n=2), endometrial cancer (n=1) or adrenal mass (n=2) within the first year after lpn

Keywords: laparoscopic partial nephrectomy trifecta pentafecta outcomes
prophylaxis roles of il-2 treatment on gvhd after transplantation

Conditions: Acute Graft-versus-host Disease

Summary: the effects of haploidentical rhg-csf-mobilized unmanipulated blood and marrow transplantation (hbmt) on hematological malignancies are well established.the aim of this prospective cohort trial is to determine if acute graft-versus-host disease (agvhd) could be decreased with il2 therapy post hbmt.

the effects of haploidentical rhg-csf-mobilized unmanipulated blood and marrow transplantation (hbmt) on hematological malignancies are well established.the aim of this prospective cohort trial is to determine if acute graft-versus-host disease (agvhd) could be decreased with il2 therapy post hbmt.low dose of il-2 (40 million u/m2) will be administered from wbc engraftment to day 90 post haploidentical transplantation. il-2 will be administered three times a week.

Eligibility criteria:
inclusion criteria: 1. aged 15-65 years old 2. acute leukemia in complete remission (cr1/cr2) who received myeloablative haploidentical allo-hsct 3. wbc engraftment (anc\>500/ul for continuous 3 days) 4. at least +7d 5. less than or equal to +15d 6. non t-all 7. no active ii-iv agvhd 8. no severe infections 9. karnofsky score greater than or equal to 90% 10. haploidentical donor from sibling, children or father 11. ensure that informed consent signed and faxed to research coordinator exclusion criteria: 1. exposure to any other clinical trials prior to enrollment 2. active malignant disease relapses or mrd positive 3. active, uncontrolled infection 4. inability to comply with il-2 treatment regimen 5. active, uncontrolled ii-iv agvhd 6. haploidentical donor from mother or collateral donors 7. clinical signs of severe pulmonary dysfunction 8. clinical signs of sever cardiac dysfunction 9. receiving corticosteroids as gvhd treatment
acromegaly & sleep apnoea

Conditions: Acromegaly

Summary: estimates of the prevalence of acromegaly, a condition resulting from excess growth hormone secretion, are as high as 1:1000. if detected late acromegaly increases the risk of joint destruction, heart disease, sleep apnoea, high blood pressure, diabetes, and polyps in the colon. to have a greater effect on long-term outcomes this disease needs to be detected early. by screening a 'high risk' population (sleep apnoea clinic) the investigators may be able to detect these patients earlier and prevent late complications of the disease. at ltht the referral pathway for new referrals to the sleep apnoea clinic involves initial attendance to pick up a pulse oximeter to wear overnight to measure oxygen levels. these readings show approximately 1:4 patients displays evidence of significant obstructive sleep apnoea to warrant referral to the treatment group for continuous positive airway pressure (cpap), weight management, and occasionally mandibular adjustment. patients attending the sleep apnoea clinic either as new referral or for review will be asked to participate in the proposed study. the study is cross-sectional in design incorporating two sub-populations within the sleep apnoea clinic. the first cohort comprises patients under follow-up known to have sleep apnoea, and the second cohort those patients prospectively attending the sleep apnoea clinic for assessment. if after an explanation of the study they agree to participate blood will be taken for assessment of igf-i and they will be asked to complete a simple questionnaire. the aim will to be to screen 1000 consecutive patients. the questionnaire will incorporate five simple questions to be completed with a 'yes' or 'no' answer. where igf-i levels are elevated patients will be investigated further for the possibility of acromegaly. the presence of biochemically proven acromegaly will be used to determine if the simple question has sufficient sensitivity to use as a screening tool.


Eligibility criteria:
inclusion criteria: * adults aged 16 and above. * referred to the sleep apnoea clinic for assessment of obstructive sleep apnoea * have capacity to given informed consent. exclusion criteria: * patients under 16 years of age * not referred to the sleep apnoea clinic * unable to give informed consent
comparison between ticagrelor versus very low dose rivaroxaban with clopidogrel

Conditions: Acute Coronary Syndrome; Acute Myocardial Infarction; Unstable Angina

Summary: a total of 50 participants diagnosed with acs (group a ticagrelor 180mg/d, n=25), group b (clopidogrel 75mg + rivaroxaban 5mg/ d, n=25)) were consecutively enrolled and treated with study drugs on top of aspirin (100mg/d) for 1 month. verifynow® and global thrombosis test were performed at day 2 and 1 month after administration of study drugs. the investigators compared aspirin reaction unit (aru) and p2y12 reaction unit (pru), occlusion time (ot) which reflects shear stress-induced thrombotic activity, and lysis time (lt) which showed endogenous lytic activity between the two strategies at both time points.


Eligibility criteria:
inclusion criteria: * patients who were diagnosed with acute coronary syndrome and underwent percutaneous coronary intervention exclusion criteria: * patients administered with glycoprotein iib/iiia inhibitiors * patients with atrial fibrillation * patients with high risk of bleeding at the physician's discretion * patients with renal impairment (estimated gfr \<30ml/min)
impact of triclosan-coated suture on surgical site infection after colorectal surgery

Conditions: Colorectal Resection

Summary: despite adequate antimicrobial prophylaxis and perioperative correction of risk factors, surgical site infections (ssi) remain the most frequent complication of colorectal resection (range 10-17%). several strategies may be implemented to prevent ssi. among these, the use of local antimicrobial agents seems successful. the primary aim of the present trial was to evaluate the efficacy of a surgical suture, coated with triclosan a synthetic soluble antimicrobial agent, in reducing the ssi rate after colorectal operations.

this was a non-sponsored, multicenter, prospective, randomized, controlled, single-blind study. two hundred and seventy-three patients candidate to colorectal resection were enrolled. exclusion criteria were: age \ 85 years, pregnancy, peritonitis, peritoneal contamination during operation, ongoing infections, asa score \> 3, denied consent. 135 were randomized to the treatment arm and 136 to the control arm. treatment consisted of abdominal wound closure by suturing peritoneum, fascia, subcutaneous tissue, and skin with polyglactin 910 triclosan-coated suture (treatment arm) or with polyglactin without triclosan (control arm). ssi were defined according to the atlanta cdc. patients were followed up by office visits for 30 days after discharge.

Eligibility criteria:
inclusion criteria: * patients candidate to elective colorectal resection exclusion criteria: * no consent * peritonitis * hypersensitivity to triclosan * asa \> 3 * ongoing infections

Keywords: triclosan colorectal surgery surgical site infection
palliative care outcomes in the management of malignant ascites by interventional radiology

Conditions: Refractory Malignant Ascites

Summary: malignant ascites leads to significant morbidity in patients with terminal cancer. paracentesis can provide relief, but repeat hospital visits, pain, and short duration of relief after paracentesis are detrimental to quality of life(qol). two devices are available as alternatives to paracentesis. the impact of either device on qol has not fully been explored. a pilot nonrandomized trial measuring palliative care qol and ascites symptom relief using validated survey instruments is proposed.


Eligibility criteria:
inclusion criteria: * refractory malignant ascites defined as ascites requiring more than one paracentesis to control patient symptoms despite medical therapy with diuretics and a. peritoneal fluid with cytology positive for malignant cells or * known malignancy with imaging findings of peritoneal carcinomatosis . * eastern cooperative oncology group (ecog) performance score 3 * age greater than or equal to 18 * capable of giving informed consent exclusion criteria: * life expectancy less than one month * coagulopathy defined as international normalized ration (inr) \>2 which cannot be corrected with fresh frozen plasma * platelet count \<50,000/microliter, which cannot be corrected with platelet transfusion * active skin infections at sites where pvs would be inserted * presence of infectious peritonitis or bacteremia * neutropenia * american heart association class d congestive heart failure (ie new york heart association class iv) * stage 5 ckd (ie gfr \< 15 ml/min) * severe hypoalbuminemia defined as \< 2.2 g/dl * loculated or hemorrhagic ascites * history of bleeding gastroesophageal varices * inability to provide informed consent * unable to participate in neuropsychological tests / questionnaires * pregnant or nursing women * anasarca

Keywords: adult patients with refractory malignant ascites secondary to gu or gi malignancy.
qualitative techniques to define meaningful within-patient change in symptoms of advanced cancer patients

Conditions: Hematopoietic and Lymphoid System Neoplasm; Malignant Solid Neoplasm

Summary: this study examines qualitative techniques in defining meaningful within patients changes in symptoms in patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). this study may help researcher better understand how to interpret reports from patients about their cancer symptoms and treatment side effects.

primary objectives: i. to develop method to establish meaningful change in patient-reported outcomes (pros). ii. to provide responder definitions in 2 ways: iia: detectable change: within patient score change patients perceive but does not exceed a subjective threshold for a modification to patient care (for worsening) or conclusion of achieving therapeutic benefit (for improvement); iib. meaningful change: within patient score change that patients perceive and that does require modification in management (for worsening) or supports conclusion of therapeutic benefit (improvement). outline: this is an observational study. participants are assigned to 1 of 2 groups. patients: patients take part in an interview on study. patient advocates: patient advocate participants take part in an interview on study.

Eligibility criteria:
inclusion criteria: * patients * patients with a diagnosis of cancer including solid tumor and hematologic malignancy at mayo clinic, rochester * to ensure sampling patients likely to have experienced declines in fatigue, all patients will have had at least two in-person encounters for radiation or chemotherapy treatment within the 3 months prior to recruitment. the sampling methodology developed for the consumer assessment of healthcare providers and systems (cahps) cancer care survey will be modified and used to identify eligible patients from mayo clinic's electronic health record * as interviews will be conducted either in person or by video conference (zoom, teams, or similar), access to internet is required for those unable or unwilling to travel to the clinic for an in-person interview * answered "yes" to screening question: "in the past 3 months, have you experienced changes in your level of fatigue?" yes/no * patient advocates: * patient advocates recommended by the fda to provide their input to help us in reaching a consensus in the way we define meaningful change (both improvement and decline) that came from patients in the first arm exclusion criteria: * patients * unwilling to be audio recorded during the interviews * answered "no" for the screening question
retrospective evaluation of the radiographic efficacy of conventional and biologic treatment

Conditions: Rheumatoid Arthritis

Summary: this study involves review and analysis of disease activity in patients with rheumatoid arthritis who where treated with either conventional dmards (disease modifying antirheumatic drugs) or biologics and have two existing, consecutive radiographs (x-ray images) of hand and feet taken as part of routine treatment monitoring within a time interval of 12 to 36 months.


Eligibility criteria:
inclusion criteria: * secure diagnosis of rheumatoid arthritis * older than 18 years * two consecutive plain radiographs of the hands and feet with a time interval of 12 to 36 months are available. the radiographs are recorded 2003 or later and are in accordance with a defined x-ray protocol. exclusion criteria: - patients who receive anakinra, rituximab or abatacept
effect of health education on female teachers' knowledge and practices regarding early breast cancer detection and screening in the jazan area: a quasi-experimental study

Conditions: Effect of Health Education Regarding Screening Tools of Breast Cancer

Summary: the purpose of this study is to assess the effectiveness of health education in improving the knowledge and practices of female teachers regarding screening tools and the early detection of breast cancer.

a two-group quasi-experimental design was conducted among 150 female teachers, who were selected from 75 schools of the jazan general administration of education. schools were chosen by a simple cluster randomization method. schools were non-randomly assigned to either the intervention or control group. eligible participants were recruited by a simple randomization method, proportional to the total number of teachers at each school. those in the intervention group (n=75 teachers) were compared to the control group (n=75 teachers) at baseline, as well as at 6 weeks and 3 months post-intervention. study aim: assess effectiveness of health education on improving knowledge and practices regarding breast cancer(bc) early detection and screening tools among female teachers after six weeks, three months in health education group in compare with control group. specific objectives: estimate level of awareness among female teachers regarding knowledge and practices of bc early detection and screening tools in jazan area schools. measure the impact of health education on female teachers knowledge and practices regarding bc early detection and screening tools in health education group in compare with control group. so research questions are: what is the current awareness level of female teachers in jazan area schools regarding knowledge and practices of bc early detection and screening tools? does health education improve knowledge and practices regarding bc early detection and screening tools among female teachers in jazan area schools in health education group more than control group?

Eligibility criteria:
inclusion criteria: * 20 years. no personal history of bc. no first degree relative of bc. not being pregnant or breast feeding. ability to understand questionnaire exclusion criteria: refused to give informed consent. sever medical problem prevent participation.

Keywords: breast cancer screening; health education; breast self-examination; clinical breast examination; mammography.